306 related articles for article (PubMed ID: 18927302)
1. Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species.
Roy R; Louis G; Loughlin KR; Wiederschain D; Kilroy SM; Lamb CC; Zurakowski D; Moses MA
Clin Cancer Res; 2008 Oct; 14(20):6610-7. PubMed ID: 18927302
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic value of neutrophil gelatinase-associated lipocalin/matrix metalloproteinase-9 pathway in transitional cell carcinoma of the bladder.
Candido S; Di Maso M; Serraino D; McCubrey JA; Bortolus R; Zanin M; Battiston M; Salemi R; Libra M; Polesel J
Tumour Biol; 2016 Jul; 37(7):9855-63. PubMed ID: 26810191
[TBL] [Abstract][Full Text] [Related]
3. Urinary gelatinase activities (matrix metalloproteinases 2 and 9) in human bladder tumors.
Di Carlo A; Terracciano D; Mariano A; Macchia V
Oncol Rep; 2006 May; 15(5):1321-6. PubMed ID: 16596205
[TBL] [Abstract][Full Text] [Related]
4. Excretion of matrix metalloproteinases 2 and 9 in urine is associated with a high stage and grade of bladder carcinoma.
Gerhards S; Jung K; Koenig F; Daniltchenko D; Hauptmann S; Schnorr D; Loening SA
Urology; 2001 Apr; 57(4):675-9. PubMed ID: 11306379
[TBL] [Abstract][Full Text] [Related]
5. The value of combined use of survivin mRNA and matrix metalloproteinase 2 and 9 for bladder cancer detection in voided urine.
Eissa S; Badr S; Elhamid SA; Helmy AS; Nour M; Esmat M
Dis Markers; 2013; 34(1):57-62. PubMed ID: 22960341
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder.
Durkan GC; Nutt JE; Rajjayabun PH; Neal DE; Lunec J; Mellon JK
Clin Cancer Res; 2001 Nov; 7(11):3450-6. PubMed ID: 11705862
[TBL] [Abstract][Full Text] [Related]
7. Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: a comparison with clinically used tumor markers.
Sier CF; Casetta G; Verheijen JH; Tizzani A; Agape V; Kos J; Blasi F; Hanemaaijer R
Clin Cancer Res; 2000 Jun; 6(6):2333-40. PubMed ID: 10873084
[TBL] [Abstract][Full Text] [Related]
8. Alteration in urinary matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio predicts recurrence in nonmuscle-invasive bladder cancer.
Durkan GC; Nutt JE; Marsh C; Rajjayabun PH; Robinson MC; Neal DE; Lunec J; Mellon JK
Clin Cancer Res; 2003 Jul; 9(7):2576-82. PubMed ID: 12855633
[TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinase and heparin-stimulated serine proteinase activities in post-prostate massage urine of men with prostate cancer.
Muñoz D; Serrano MK; Hernandez ME; Haller R; Swanson T; Slaton JW; Sinha AA; Wilson MJ
Exp Mol Pathol; 2017 Dec; 103(3):300-305. PubMed ID: 29175302
[TBL] [Abstract][Full Text] [Related]
10. MMP-2 and MMP-9 as prognostic markers for the early detection of urinary bladder cancer.
Fouad H; Salem H; Ellakwa DE; Abdel-Hamid M
J Biochem Mol Toxicol; 2019 Apr; 33(4):e22275. PubMed ID: 30548095
[TBL] [Abstract][Full Text] [Related]
11. Urinary biomarkers predict brain tumor presence and response to therapy.
Smith ER; Zurakowski D; Saad A; Scott RM; Moses MA
Clin Cancer Res; 2008 Apr; 14(8):2378-86. PubMed ID: 18413828
[TBL] [Abstract][Full Text] [Related]
12. Increased incidence of matrix metalloproteinases in urine of cancer patients.
Moses MA; Wiederschain D; Loughlin KR; Zurakowski D; Lamb CC; Freeman MR
Cancer Res; 1998 Apr; 58(7):1395-9. PubMed ID: 9537238
[TBL] [Abstract][Full Text] [Related]
13. Matrix metalloproteinase-9 measured in urine from bladder cancer patients is an independent prognostic marker of poor survival.
Offersen BV; Knap MM; Horsman MR; Verheijen J; Hanemaaijer R; Overgaard J
Acta Oncol; 2010 Nov; 49(8):1283-7. PubMed ID: 20843171
[TBL] [Abstract][Full Text] [Related]
14. Matrix metalloproteinase-2 and -9 in the urine of prostate cancer patients.
Di Carlo A; Mariano A; Terracciano D; Ferro M; Montanaro V; Marsicano M; Di Lorenzo G; Altieri V; Macchia V
Oncol Rep; 2010 Jul; 24(1):3-8. PubMed ID: 20514437
[TBL] [Abstract][Full Text] [Related]
15. Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine.
Eissa S; Ali-Labib R; Swellam M; Bassiony M; Tash F; El-Zayat TM
Eur Urol; 2007 Nov; 52(5):1388-96. PubMed ID: 17466450
[TBL] [Abstract][Full Text] [Related]
16. Urinary MMP-2 and MMP-9 predict the presence of ovarian cancer in women with normal CA125 levels.
Coticchia CM; Curatolo AS; Zurakowski D; Yang J; Daniels KE; Matulonis UA; Moses MA
Gynecol Oncol; 2011 Nov; 123(2):295-300. PubMed ID: 21889192
[TBL] [Abstract][Full Text] [Related]
17. Urinary high molecular weight matrix metalloproteinases as non-invasive biomarker for detection of bladder cancer.
Mohammed MA; Seleim MF; Abdalla MS; Sharada HM; Abdel Wahab AH
BMC Urol; 2013 May; 13():25. PubMed ID: 23672427
[TBL] [Abstract][Full Text] [Related]
18. Editorial comment on: Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine.
Babjuk M
Eur Urol; 2007 Nov; 52(5):1396-7. PubMed ID: 17466449
[No Abstract] [Full Text] [Related]
19. The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL.
Yan L; Borregaard N; Kjeldsen L; Moses MA
J Biol Chem; 2001 Oct; 276(40):37258-65. PubMed ID: 11486009
[TBL] [Abstract][Full Text] [Related]
20. Urinary ADAM12 and MMP-9/NGAL complex detect the presence of gastric cancer.
Shimura T; Dagher A; Sachdev M; Ebi M; Yamada T; Yamada T; Joh T; Moses MA
Cancer Prev Res (Phila); 2015 Mar; 8(3):240-8. PubMed ID: 25591790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
